期刊文献+

浅析舒洛地特联合辛伐他汀对提高糖尿病下肢血管病变治疗效果的有效性 被引量:11

Analysis of Sulodexide Combined With Simvastatin on the Effectiveness and Improve the Effect of the Treatment of Diabetic Lower Extremity Vascular Disease
下载PDF
导出
摘要 目的分析舒洛地特与辛伐他汀联合治疗糖尿病并发下肢血管疾病的效果。方法收集40例糖尿病并发下肢血管疾病患者,用舒洛地特和辛伐他汀联合治疗,对比治疗前后情况。结果和治疗前相比,治疗后最大行走与无痛行走的距离增加;足部动脉血流速度、阻力指数、踝肱指数及搏动指数等改善;血生化指标明显降低(P<0.05)。结论舒洛地特与辛伐他汀治疗高糖尿病患下肢血管意义重大。 Objective To analyze the application of sulodexide and simvastatin in treatment of diabetic patients with lower extremity vascular disease effect. Methods To collect 40 cases of diabetes complicated with lower extremity vascular disease patients, sulodexide and simvastatin treatment, contrast before and after the treatment. Results Compared with before treatment, after treatment the maximum walking and pain free walking distance increased, the foot artery blood flow velocity, resistance index, ankle brachial index and pulsatility index improvement, blood biochemical indexes decreased significantly(P〈0.05). Conclusion Sulodexide and simvastatin in the treatment of diabetic patients with lower extremity vascular significant high.
作者 陶静
出处 《中国继续医学教育》 2015年第5期224-225,共2页 China Continuing Medical Education
关键词 舒洛地特 辛伐他汀 糖尿病 下肢血管病变 治疗有效性 Sulodexide Simvastatin Diabetes Lower extremity vascular disease Treatment effectiveness
  • 相关文献

参考文献2

二级参考文献34

  • 1刘芳,曾辉,沈娟,赵俊功,赵珺,包玉倩,贾伟平.门诊2型糖尿病足高危患者的踝肱指数与糖尿病足的相关性研究[J].中华糖尿病杂志,2010,2(1). 被引量:13
  • 2李红.糖尿病微血管病变发病机制和治疗靶点[J].浙江大学学报(医学版),2006,35(3):233-237. 被引量:41
  • 3Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev, 1998,18(1) : 1-20.
  • 4Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev, 2006,24 ( 3- 4) : 214-226.
  • 5Crepaldi G, Rossi A, Coscetti G, et al. Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exp Clin Res, 1992,18(5) :189-195.
  • 6Tiozzo R, Cingi MR, Pietrangelo A, et al. Effect of heparinlike compounds on the in vitro proliferation and protein synthesis of various cell types. Arzneimitteforschung, 1989, 39 (1) : 15-20.
  • 7Williams ME. New potential agents in treating diabetic kidney disease: the fourth act. Drugs, 2006, 66 (18) : 2287- 2298.
  • 8Ceol M, Gambaro G, Sauer U, et al. Glycosaminoglycan therapy prevents TGF-betal overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol, 2000,11 ( 12 ) : 2324-2336.
  • 9Lauver DA, Booth EA, White AJ, et al. Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther, 2005,312(2) : 794- 800.
  • 10Karon J, Poubinska A, Antoniewicz AA, et al. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif, 2007,25(5-6) :510-514.

共引文献20

同被引文献49

  • 1田娜.他汀类药物在糖尿病血管病变应用的新进展[J].慢性病学杂志,2013,13(11):840-842. 被引量:4
  • 2吴伯军.2型糖尿病患者尿微量白蛋白与下肢血管病变的关系[J].中国药物经济学,2013,8(3):193-194.
  • 3Masola,V., Zaza, G., Gambaro, G,et al. Sulodexide and gly- cosaminoglycans in the progression of renal disease []]. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association- Euro- pean Renal Association,2014,29:i74-i79.
  • 4Hilary J. Bews,Jules C. Carlson,Aruni Jha, et al.Simuhaneous quantification of simvastatin and simvastatin hydroxy acid in blood serum at physiological pH by ultrahigh performance liquid chromatography-tandem mass spectrometry (UHPLC/ MS/MS)[J].Journal of chromatography, B,Analytical technolo- gies in the biomedical and life sciences,2014,947/948:145- 150.
  • 5Lewis EJ,Lewis JB,Greene T,et al.Sulodexide for kidney protecfion in type 2 diabetes patiens with micro-albuminuria:A randomized controlled trial[J].Am J Kidney Dis,2013,56(9):256-259.
  • 6Gladdi AV,Cicero AF,Gambaro G.Nephroprotective action of glycosaminoglycans:Why the pha-rmacological properties of sulodexide might be reconsidered[J].Int J Nephrol Renovasc Dis,2013,80(9):734-743.
  • 7Khanna R.Clinical presentation&management of glomenrular diseases:hematuria,nephritic&nephrotic syndrome[J].Missouri Med,2011,108(1):33-36.
  • 8Cirujeda JL,Granado PC.A study on the safety,efficacy,and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis[J].Angiology,2006,57(1):53-64.
  • 9宋梅,李海英.可溶性P-选择素与糖尿病下肢血管病变的相关性[J].中国药物经济学,2013,3(4):293-295.
  • 10Lei Y, Zhang Z, Wang Y, et al.Sulodexide may alleviate neointimal hyperplasia by inhibiting angiopoietin 2in anarteriove-nousfistulamodel~[J].MolMedRep,2013,7(3):831-835.

引证文献11

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部